Sector News

Mylan throws out Teva bid

April 28, 2015
Life sciences
As expected, Mylan’s board has unanimously and vehemently rejected Teva’s takeover offer of around $40 billion, slamming the proposal for “grossly undervaluing” the firm.
 
Following weeks of speculation, Teva finally made an official, unsolicited move on the firm last week offering $82 per Mylan share in a 50/50 cash/stock transaction.
 
The marriage, Teva said, would create a generics powerhouse with pro forma 2014 annual sales of around $30 billion, though Mylan hasn’t seemed sold on the idea from the start.
 
And today Mylan’s board said Teva’s approach contains nothing that would prompt it to depart from a “successful and longstanding standalone strategy”.
 
Lacking logic
“Teva’s proposal grossly undervalues Mylan, and would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk,” noted executive chairman Robert Coury.  
 
In a hard-hitting letter to Teva, Coury said Mylan’s board would not even enter into any discussions regarding an offer unless the starting point was “significantly in excess of $100 per share.”
 
“We also believe that the proposal does not address the serious challenges of integrating two fundamentally different and conflicting cultures under a Teva Board and leadership team with a poor record of delivering sustainable shareholder value,” he said. 
 
Teva responded by saying it remains fully committed to completing the merger.
 
By Selina McKee
 
Source: Pharma Times

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend